Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
Sarah Cannon Research Institute, Denver, Colorado Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami, Florida Massachusetts General Hospital, Boston, Massachusetts Sarah Cannon Research Institute, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas NEXT Oncology, San Antonio, Texas